257 related articles for article (PubMed ID: 35017699)
21. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
[TBL] [Abstract][Full Text] [Related]
22. Effect of Intravitreal Aflibercept vs Laser Photocoagulation on Treatment Success of Retinopathy of Prematurity: The FIREFLEYE Randomized Clinical Trial.
Stahl A; Sukgen EA; Wu WC; Lepore D; Nakanishi H; Mazela J; Moshfeghi DM; Vitti R; Athanikar A; Chu K; Iveli P; Zhao F; Schmelter T; Leal S; Köfüncü E; Azuma N;
JAMA; 2022 Jul; 328(4):348-359. PubMed ID: 35881122
[TBL] [Abstract][Full Text] [Related]
23. Risk of recurrence of retinopathy of prematurity after initial intravitreal ranibizumab therapy.
Chan JJT; Lam CPS; Kwok MKM; Wong RLM; Lee GKY; Lau WWY; Yam JCS
Sci Rep; 2016 Jun; 6():27082. PubMed ID: 27256987
[TBL] [Abstract][Full Text] [Related]
24. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
[TBL] [Abstract][Full Text] [Related]
25. Refractive Outcomes of 4-Year-old Children after Intravitreal Anti-vascular Endothelial Growth Factor versus Laser Photocoagulation for Retinopathy of Prematurity.
Kang HG; Kim TY; Han J; Han SH
Korean J Ophthalmol; 2019 Jun; 33(3):272-278. PubMed ID: 31179659
[TBL] [Abstract][Full Text] [Related]
26. Anti-vascular endothelial growth factor intravitreal therapy for retinopathy of prematurity.
VanderVeen DK; Cataltepe SU
Semin Perinatol; 2019 Oct; 43(6):375-380. PubMed ID: 31174872
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal anti-VEGF therapy as a treatment for retinopathy of prematurity: what we know after 7 years.
Klufas MA; Chan RV
J Pediatr Ophthalmol Strabismus; 2015; 52(2):77-84. PubMed ID: 25798707
[TBL] [Abstract][Full Text] [Related]
28. Reactivation of retinopathy of prematurity six years after intravitreal injection of bevacizumab.
Yasin A; Sinha S; Smith R; Jain SF; Hejkal T; Rychwalski P
J AAPOS; 2023 Aug; 27(4):236-239. PubMed ID: 37451499
[TBL] [Abstract][Full Text] [Related]
29. FACTORS ASSOCIATED WITH REACTIVATION AFTER INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB THERAPY IN INFANTS WITH RETINOPATHY OF PREMATURITY.
Iwahashi C; Utamura S; Kuniyoshi K; Sugioka K; Konishi Y; Wada N; Kusaka S
Retina; 2021 Nov; 41(11):2261-2268. PubMed ID: 33958533
[TBL] [Abstract][Full Text] [Related]
30. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series.
Martínez-Castellanos MA; González-H León A; Romo-Aguas JC; Gonzalez-Gonzalez LA
Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):767-772. PubMed ID: 31953595
[TBL] [Abstract][Full Text] [Related]
31. SERUM VASCULAR ENDOTHELIAL GROWTH FACTOR AFTER BEVACIZUMAB OR RANIBIZUMAB TREATMENT FOR RETINOPATHY OF PREMATURITY.
Wu WC; Shih CP; Lien R; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
Retina; 2017 Apr; 37(4):694-701. PubMed ID: 27467377
[TBL] [Abstract][Full Text] [Related]
32. Vascular endothelial growth factor plasma levels before and after treatment of retinopathy of prematurity with ranibizumab.
Zhou Y; Jiang Y; Bai Y; Wen J; Chen L
Graefes Arch Clin Exp Ophthalmol; 2016 Jan; 254(1):31-6. PubMed ID: 25851862
[TBL] [Abstract][Full Text] [Related]
33. Low dose versus conventional dose of intravitreal bevacizumab injection for retinopathy of prematurity: a case series with paired-eye comparison.
Han J; Kim SE; Lee SC; Lee CS
Acta Ophthalmol; 2018 Jun; 96(4):e475-e478. PubMed ID: 27011262
[TBL] [Abstract][Full Text] [Related]
34. Anti-Vascular Endothelial Growth Factor Therapy for Primary Treatment of Type 1 Retinopathy of Prematurity: A Report by the American Academy of Ophthalmology.
VanderVeen DK; Melia M; Yang MB; Hutchinson AK; Wilson LB; Lambert SR
Ophthalmology; 2017 May; 124(5):619-633. PubMed ID: 28341474
[TBL] [Abstract][Full Text] [Related]
35. Timing of laser following intravitreal anti-vascular endothelial growth factor injections for aggressive posterior zone 1 retinopathy of prematurity.
Vinekar A
Indian J Ophthalmol; 2021 Aug; 69(8):1988-1989. PubMed ID: 34304161
[No Abstract] [Full Text] [Related]
36. Study protocol for prognosis and treatment strategy of peripheral persistent avascular retina after intravitreal anti-VEGF therapy in retinopathy of prematurity.
Yu Y; Wang J; Chen F; Chen W; Jiang N; Xiang D
Trials; 2020 Jun; 21(1):493. PubMed ID: 32513245
[TBL] [Abstract][Full Text] [Related]
37. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
Tan QQ; Christiansen SP; Wang J
PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
[TBL] [Abstract][Full Text] [Related]
38. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP).
Li Z; Zhang Y; Liao Y; Zeng R; Zeng P; Lan Y
BMC Ophthalmol; 2018 Jan; 18(1):19. PubMed ID: 29378530
[TBL] [Abstract][Full Text] [Related]
39. Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.
Chung EJ; Kim JH; Ahn HS; Koh HJ
Graefes Arch Clin Exp Ophthalmol; 2007 Nov; 245(11):1727-30. PubMed ID: 17690897
[TBL] [Abstract][Full Text] [Related]
40. [Long-term effects of anti-VEGF therapy for retinopathy of prematurity].
Krohne TU; Müller A; Larsen PP; Holz FG
Ophthalmologe; 2018 Jun; 115(6):464-468. PubMed ID: 29654389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]